Brought to you by 
Teva could expand Treanda life cycle with Eagle's EP3102
15 Apr 2019
Executive Summary
Teva Pharmaceutical Industries Ltd. received exclusive US and Canadian commercialization, promotion, and distribution rights to Eagle Pharmaceuticals Inc.'s NDA-filed EP3102 (bendamustine) for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva could expand Treanda life cycle with Eagle's EP3102
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice